CATALAYER NEWS
TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO – Company Announcement - FT.com - Financial Times
Source: Financial Times · 2026-10-25
Full article text is available in the Catalayer news terminal.
CATALAYER AI PUBLIC BRIEF
Summary
ENERGY SUPPLYMEDIUM
Event KB match: "Hyundai warns Middle East conflict disrupting expo" (proven energy_supply pattern). Known impact chain: energy_prices, transportation_costs. Importance: medium (conservative assessment).
Market Impact
▼Bearish· Moderate magnitude
Key variables: energy prices, transportation costs
Affected sectors: energy, financials
Market Prediction
◆
████ ████
◆
████ ████
◆
████ ████
Unlock full Catalayer AI Analysis with Plus
Full analysis includes market prediction, what to watch, signal chain, and monitor-ready context. Powered by Catalayer AI.
Analysis by Catalayer AI · 11102 knowledge records · catalayer.com
MORE FROM FINANCIAL TIMES
Marco Rubio still owes Europe answers about America’s intentions - Financial Times
2026-10-25
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in Firs
2026-10-25
Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancer
2026-10-25
Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvaluma
2026-10-25
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12
2026-10-25
RELATED ON CATALAYER
RELATED MARKETS
Prediction Markets